CLOs on the Move

Ocularis Pharma

www.ocularispharma.com

 
Ocularis Pharma, Inc. is a Riverside, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Clinical DataFax Systems

Clinical DataFax Systems, Inc. is a Hamilton, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Dsr Pharmaceuticals

Dsr Pharmaceuticals is a Playa Del Rey, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BPL Plasma

Part of UK-based Bio Products Laboratory, BPL Plasma has been a global leader in the plasma collection industry for more than 25 years. We`re proud to support the creation & manufacturing of lifesaving drug therapies by supplying high-quality plasma to people in need. At BPL Plasma, the people who walk into our centers are much more than donors — they are lifelines. Their donation, quite literally, transforms the lives of patients around the planet. Donating plasma makes it possible for: - An expectant mother to carry her child safely to term. - A little boy with hemophilia to experience a healthy, happy childhood. - A wounded warrior or burn victim to begin the healing process.

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia

New Freedom

New Freedoms 90-day reentry program inspires personal growth and accountability while treating substance abuse and other behavioral health needs.